Compare PRHI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRHI | PHGE |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | PRHI | PHGE |
|---|---|---|
| Price | $0.59 | $4.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.9K | ★ 64.4K |
| Earning Date | 03-09-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.25 |
| 52 Week High | $2.83 | $8.50 |
| Indicator | PRHI | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 45.74 |
| Support Level | $0.53 | $0.53 |
| Resistance Level | $0.87 | $6.28 |
| Average True Range (ATR) | 0.06 | 1.05 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 6.07 | 24.32 |
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).